Trust should be an evidence decision. Eight questions help pharma and biotech buyers test how an AI provider uses, retains, accesses, routes, governs, and protects sensitive information.
Alenvo Regulatory Team · 10 min read
Published
Yes, but only when trust is earned through evidence and matched to the intended use. Before sensitive drug-development information is uploaded, a buyer should be able to verify how the provider uses, retains, accesses, routes, monitors, and contractually protects that information, and how the AI system is governed over time.
Consider an illustrative biotech company evaluating an AI platform for an IND-readiness pilot. The proposed upload includes an unpublished toxicology report, Investigator's Brochure, clinical protocol, CMC development summary, and regulatory correspondence. The demonstration is impressive. Procurement asks a more important question: what evidence should we see before any of those files leave our controlled environment?
Vendor review should start with context of use and information classification. A demonstration using public literature does not create the same exposure as a pilot using confidential CMC records. Personal data adds privacy obligations. Records or outputs used in a regulated workflow may add quality, validation, documentation, and change-control expectations. The decision should identify both the information entering the system and the decision or record the output may influence.
The FDA and EMA's 2026 principles for good AI practice in drug development emphasize a risk-based approach, a clear context of use, multidisciplinary expertise, data governance and documentation, performance assessment, and lifecycle management. They are guiding principles, not a vendor certification or a substitute for requirements that apply to a sponsor's particular activity.
NIST's AI Risk Management Framework is a voluntary, cross-sector framework organized around governing, mapping, measuring, and managing AI risk. Its Generative AI Profile adds considerations specific to generative systems. These resources can structure diligence, but they do not determine whether a particular pharma use is compliant or validated.
| Question to ask | Evidence to request | Warning sign |
|---|---|---|
| How may our data be used? | Contract terms, privacy terms, product settings, and a written explanation of training and secondary use | Broad rights to reuse customer content or answers limited to marketing language |
| How is information deleted? | Retention schedule, backup lifecycle, deletion process, and available confirmation | No defined schedule or deletion that excludes derived data without explanation |
| Who can access it? | Role matrix, privileged-access process, access-review evidence, and tenant-separation description | Shared credentials, standing privileged access, or unclear customer separation |
| Where does it travel? | Current subprocessor list, data-flow diagram, processing locations, and change-notice terms | An incomplete list or no account of model-provider data handling |
| How are incidents handled? | Incident-response plan, monitoring scope, notification terms, and relevant exercise evidence | No notification commitment or no owner for investigating suspicious access |
| What has been independently assessed? | Current assurance report, scope, exceptions, remediation status, and contract mapping | A certification logo without scope, date, or applicable service details |
| How are outputs governed? | Human-review controls, validation or evaluation records, version history, limitations, and change process | Outputs treated as authoritative or material changes made without notice or assessment |
| How do we exit or recover? | Continuity and recovery plan, tested export, termination assistance, and record-preservation terms | Proprietary lock-in with no usable export or continuity evidence |
Suppose the provider documents acceptable data-use terms and access controls but cannot provide a defined retention schedule or enough detail about a model subprocessor. The sponsor does not need to reduce the decision to approve or reject. It can approve a public-information demonstration, approve a pilot with redacted or lower-sensitivity documents, require missing controls before confidential upload, or defer the use entirely.
The right outcome depends on the sponsor's information classification, intended use, applicable obligations, risk tolerance, and ability to add compensating controls. What matters is that the decision is based on documented facts, unresolved questions, and explicit restrictions rather than assumptions created by the word secure.
Information security, privacy and data protection, and fitness for a regulated or GxP use are related but separate determinations. A security report may support confidence that specified controls were assessed during a defined period. It does not, by itself, establish lawful processing, validate an intended use, demonstrate that an output is scientifically reliable, or make the sponsor's workflow compliant.
The reverse is also true. A technically strong model is not automatically appropriate for confidential information. A contract does not prove that controls operate effectively. Encryption does not answer whether the provider is permitted to retain or reuse content. Each form of evidence answers a different question, so procurement, security, privacy, quality, regulatory, scientific, and business owners may all need to participate according to the use case.
Trust is not a product feature that a buyer accepts on assertion. It is a scoped decision supported by evidence, documented limits, and ongoing review. That same discipline underlies regulatory readiness as a decision and the move from evidence to action.
This article is general information on public regulatory requirements. It is not regulatory or legal advice, and Alenvo is not affiliated with FDA. Read our editorial standards.
See how Alenvo helps teams connect evidence, gaps, and decisions across an IND program.
One new finding can change an asset's development plan, funding needs, regulatory strategy, and value to a potential partner. The challenge is recognizing which decisions need to be revisited.
A Phase 2 dose decision shows why connecting evidence matters more than producing another summary.
Drug development does not suffer from a lack of information. The harder problem is what that information means when a program reaches a decision point.
In-depth research and regulatory strategy briefs.
Real-world outcomes and customer success stories.
What FDA evaluates in the 30-day review, and what can stop an IND.
Refuse-to-file risk, the filing review, and first-cycle approval risk.
Reading a deal room for what is missing, and what absence is worth.